Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).
Read the original article

Tags:

Previous Article

KAIST develops sodium battery capable of rapid charging in just a few seconds​

Next Article

PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston

STAT+: Biotechs face challenges as the industry’s annua...

Jun 4, 2023

Say goodbye to the Covid-19 vaccination card. The CDC has stopped printing them

Say goodbye to the Covid-19 vaccination card. The CDC h...

Oct 4, 2023

Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead

Bayer’s new CEO was dealt a duo of ‘clearing events.’ T...

Nov 21, 2023